RAS Mutation Screening Panel
Cat Number: RAS-RT50
The RAS Mutation Screening Panel is a PCR-based assay that detects somatic mutations in exons 2, 3, and 4 of KRAS and NRAS genes, which are linked to cancer and resistance to anti-EGFR therapies.
- 50 tests per kit
- 8 Reactions per sample
- 2-hour turnaround time
- Works with FFPE and fresh frozen samples
- For research use (RUO) in the U.S
- For in vitro diagnostic use (IVD) in the European Union
Mutations in the KRAS gene, commonly found in metastatic colorectal cancer (mCRC), lung adenocarcinoma, and thyroid cancer, can make tumors resistant to anti-EGFR treatments. Studies show that mutations in exons 2, 3, and 4 of the KRAS and NRAS genes reduce the effectiveness of these therapies, leading experts, including the American Society of Clinical Oncology (ASCO), to recommend genetic screening before treatment.
The RAS mutation analysis real-time assay utilizes allele-specific PCR, ensuring accurate detection using fluorescent hydrolysis probes. The panel is a qualitiavive test that detects somatic mutations found in exons 2, 3, and 4 of KRAS and NRAS genes. Below is a list of mutations detected by this kit.
The RAS Mutation Screening Panel identifies the presence of the mutations in a total of 8 reactions per sample. The test does not distinguish between mutations within each group.
*A complementary add-on reaction that distinguishes KRAS G12C from other codon 12 mutations is available, upon request.
| Gene | Mutation | Group | Percent (%) Prevalance1 Colorectal Carcinoma |
Percent (%) Prevalance1 Colorectal Adenocarcinoma |
| KRAS | G12A, G12D, G12R, G12V, G13D | 1 | 33.59 | 31.41 |
| G12C*, G12S | 2 | 5.71 | 4.89 | |
| Q61H, Q61L, Q61R, A59E, A59G, A59T | 3 | 3.17 | 2.75 | |
| K117N, K117R, K117E | 4 | 0.9 | 0.92 | |
| A146T, A146P, A146V | 5 | 2.74 | 3.24 | |
| NRAS | G12D, G12C, G12S, G13R, G13V, K117R | 6 | 1.28 | 1.27 |
| Q61H, Q61L, Q61K, Q61R | 7 | 2.26 | 2.35 | |
| A59D, A59T, A146T | 8 | No Data | No Data |
1 My Cancer Genome; www.mycancergenome.org (Colorectal Carcinoma, Colorectal Adenocarcinoma)
The RAS Mutation Screening Panel follows a simple and easy to use process. The RAS Mutation Screening Kit can be completed in 2 hours and follows a far less complicated process.
EntroGenʼs RAS mutation screening panel requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.
Columns and reagents for DNA isolation are not included. Genomic DNA from FFPE tissues can be extracted using EntroGen pureNA® Genomic DNA Isolation Kit.
We suggest using the Internal Quality Control Assay (cat. no. IQCA–RT50) to determine the optimal amount of input DNA prior to running this assay.
Click above to see how it works
Click to download lot-specific quality control data for your product:
